Former President Donald Trump has floated a new economic strategy aimed at reducing pharmaceutical drug prices in the United States. The plan involves imposing a 100% tariff on branded drugs and their active ingredients produced by companies that fail to strike deals to lower costs for American consumers.
This policy specifically targets branded medications, which typically carry higher prices, while exempting generic drugs—accounting for over 90% of drugs sold domestically—for at least one year. Additionally, certain specialty drugs, including those for orphan diseases, veterinary use, and urgent public health needs from trade deal nations, will also be exempt from these tariffs.
"The goal is simple: to bring down the cost of prescription drugs for American workers and families," Trump stated in his announcement.
The proposed tariffs are part of Trump’s broader push to prioritize American interests in key industries, including healthcare. Critics have long argued that pharmaceutical companies prioritize profits over affordable access to medications, particularly for middle- and working-class Americans. By leveraging tariffs, Trump seeks to force renegotiations that could benefit domestic consumers.
However, the proposal has already drawn skepticism from some economists and industry experts, who warn that such high tariffs could lead to supply chain disruptions and potential retaliatory measures from trade partners. The policy’s impact on American drug manufacturers and its broader economic implications remain under scrutiny.
This announcement marks Trump’s latest effort to reshape U.S. trade and economic policies, continuing his focus on economic nationalism and domestic-centric reforms.